Biological Skin Substitutes Market – By Type, By Application, By End Use – Global Forecast, 2025 – 2034

Biological Skin Substitutes Market Size

The global biological skin substitutes market was valued at USD 335.1 million in 2024. The market is expected to grow to 758.2 million by 2034, at a CAGR of 8.5%. The increasing prevalence of chronic wounds and the rising number of burn and trauma cases are contributing to the growth of the market.
 

Chronic wounds like venous leg ulcers, diabetic ulcers, and pressure ulcers, are becoming more prevalent due to factors like an aging population, diabetes, and obesity. Such wounds frequently require advanced wound care like biological skin substitutes for adequate healing. For example, NIH reports that there are 9.1 to 26.1 million new cases of diabetic foot ulcers every year, which affect 15% to 25% of all diabetes patients during their lifetime. As chronic wounds become more common, the demand for biological skin substitutes increases.
 

Furthermore, burns and trauma cases from accidents or surgeries often result in large and complex wounds. In such cases, biological skin substitutes are particularly useful as they act as scaffolds for tissue growth. The National Library of Medicine (NLM) in India reports 6-7 million burn cases annually, while the American Association for the Surgery of Trauma reports more than 150,000 deaths and 3 million non-fatal injuries in the U.S. every year. Global injuries account for more than 5 million deaths every year. As such, the increasing burden of traumatic injuries increases the need for advanced biological skin substitutes and other wound care products.
 

Biological skin substitutes are advanced materials, either synthetic or natural, that aid in restoring or supporting damaged tissue caused by burns, chronic wounds, or loss of skin. Such material is usually acquired from human or animal tissues such as allografts, xenografts, and bioengineered cellular constructs, which aid in wound healing, revascularization, and tissue regeneration by functioning-like skin.
 

Biological Skin Substitutes Market Trends

• The progress made in regenerative medicine has enabled the creation of advanced biological skin substitutes. These innovations aim to closely imitate natural skin to improve wound healing.
   
• For instance, AVITA Medical Inc. has introduced their RECELL System. This product focuses on treating full-thickness skin defects. The system ultra-filters skin tissue to retrieve the desired structural components, developing a Skin Regenerative Cell Suspension, also known as Spray-On Skin Cells. These provide bedazzling results by enhancing healing and neutralizing the wound bed to pigment. Thus, more patients and medical professionals are opting for these solutions, which in turn, grows this market more.
   
• Furthermore, the healthcare sector has also witnessed the introduction and the growth of these standalone facilities which provide wound care, diabetic ulcers treatment, thus wound care centers and wound care clinics are emerging. These centers are equipped with advanced technologies and staffed by trained professionals to ensure effective care.
   
• Consequently, as the advancement and knowledge of these specialized wound treatment clinics grow, the biological products market will also grow as comprehensive care for skin wounds becomes more popular and seamless.
   

Biological Skin Substitutes Market Analysis

In 2021, the global market was valued at USD 266.4 million. The following year, it saw a slight increase to USD 287.3 million, and by 2023, the market further climbed to USD 310.2 million. Based on type, the market is segmented into human donor tissue-derived products, acellular animal-derived products, tissue-engineered skin products, and biosynthetic skin products. The human donor tissue-derived products segment dominates the market with a share of 65.8% in 2024.
 

• These products are proficient at mimicking human skin and ensuring appropriate integration and tissue development. Moreover, their reliable performance during extensive clinical studies and real-world applications has helped in ensuring trust and reliability towards human donor tissue-derived products.
   
• Additionally, availability of approved human donor tissue-derived products that comply with regulatory policies further enhances the understanding of these products and services, resulting in higher consumption. Moreover, the patient acceptability rate of the said products is equally as high, which increases their market share.
   

Based on application, the biological skin substitutes market is classified into acute wounds, chronic wounds, and other applications. The acute wounds segment dominated the market with a share of 59.4% in 2024.
 

• Acute wounds that includes surgical wound, traumatic injuries, and other emergency situations often require advanced skin substitutes for effective healing. These skin substitutes are considered the most effective solutions as they provide timely care for wounds.
  
   
• Moreover, there is a shift from traditional skin grafting methods to more advanced techniques such as minimally invasive surgery, which contributes to the growing demand for skin substitutes during the treatment of acute wounds.
   

Based on end use, the biological skin substitutes market is classified into hospitals, ambulatory surgical centers, specialty clinics, and other end users. The hospitals segment dominated the market with a share of 49.7% in 2024.
 

• Hospitals handle a variety of patients, including burn victims, trauma cases, and chronic wound patients, using biological skin substitutes. Because of their ability to handle complex cases, these healthcare institutions are in constant need of these products.
   
• In addition, specialized plastic and dermatological surgery departments, along with advanced wound care units are available in the hospital. It serves patients with multidisciplinary approach, which increases the efficiency of biologically active dressings.
   

In 2024, the U.S. led the North American market, generating a revenue of about USD 126.2 million, and anticipated to generate USD 281 million during the forecast period.
 

• The biological skin substitutes market is driven by the rising prevalence of diabetic foot ulcers, pressure ulcers, and burn injuries in the US. As per the American Medical Association (AMA), diabetic foot ulcers affects about 1.6 million people in the U.S. annually.
   
• Additionally, the market is fueled by the presence of major biotechnology companies and the growing FDA approvals for newer biological skin substitutes, such as cell and tissue engineered products.
   

Europe: UK is set to see a robust expansion in its biological skin substitutes market from 2025 to 2034.
 

• High expenditure on wound care is driving the demand for biological skin substitutes in the UK. For instance, as per the 2021 study published by National Center for Biotechnology Information that the UK spent about USD 6.2 billion for treating chronic wounds in 2021.
   
• Also, government funding for engineering biology R&D projects is a key factor that is making advanced biological skin substitutes more available for treating chronic wounds in both private and public healthcare settings in the UK.
   

Asia Pacific: Japan's biological skin substitutes market is set for lucrative growth from 2024 to 2034.
 

• In Japan, a rising number of chronic wounds and diabetic ulcers are being reported, largely attributed to the country's significant elderly demographic. As per the World Bank Group, in 2023, roughly 30% of Japan's populace is aged 65 and older. This is propelling the need for better biological skin substitutes to effectively manage skin wounds among elderly population.
   
• Additionally, availability of coverage for wound care treatments through universal healthcare system (NHI - National Health Insurance) is also promoting the adoption of advanced wound care treatment options such as biological skin substitutes in Japan.
   

Middle East and Africa: Saudi Arabia's biological skin substitutes market is expected to witness substantial growth during the forecast period.
 

• Saudi Arabia continues to have a growing demand for biological skin substitutes due to the large rates of diabetes in the country, together with the high incidence of industrial and domestic burns.
• Moreover, the region is seeing positive market growth as government policies (such as Saudi Vision 2030) aimed at improving healthcare facilities, together with investments for advanced plastic surgery and specialized wound care clinics, become more common.
   

Biological Skin Substitutes Market Share

The top five players are expected to generate 50% of the share in the market, including Integra LifeSciences, MiMedx Group, Organogenesis, Smith & Nephew, and Vericel Corporation. These companies are witnessing increasing demand for advanced wound care solutions, driving them to develop biological skin substitutes that enhance tissue regeneration and accelerate healing. Firms are focusing on improving biocompatibility, graft integration, and long-term efficacy, which is leading to innovations in bioengineered skin grafts, amniotic membrane products, and stem cell-based therapies. Leading companies in this market are collaborating with healthcare providers, research institutions, and biotechnology firms to develop regenerative solutions for hospitals, burn centers, and wound care clinics.
 

Accessibility has become a major concern in emerging markets, where economic constraints limit the adoption of high-end biological skin substitutes. Global players are facing challenges in pricing, as premium biologic grafts and cell-based therapies are available at high cost, making it easier for local manufacturers to compete. To address this issue, major companies are adjusting their pricing strategies while ensuring that their products meet performance, safety, and regulatory standards. To expand their global footprint, key players are investing in local production and strategic partnerships. Additionally, advancements in tissue engineering, 3D bioprinting, and AI-driven wound assessment are being incorporated to enhance clinical outcomes and improve patient care worldwide.
 

Biological Skin Substitutes Market Companies

Some of the eminent market participants operating in the biological skin substitutes industry include:

• Aroa Biosurgery
• Avita Medical
• BioTissue
• Integra LifeSciences
• MiMedx Group
• Misonix (Bioventus)
• Organogenesis
• ProgenaCare
• Smith & Nephew
• Stratatech Corporation (Mallinckrodt Pharmaceuticals)
• Stryker
• Tissue Regenix
• Vericel Corporation
   
• Smith & Nephew : The company is known for its extensive range of biological skin substitutes and focuses on wound management, orthopedic reconstruction, as well as sports medicine. The company has expertise in the advanced surgical products, especially used in the repair and reconstruction of joints.
   
• Stryker: The company offers advanced and comprehensive solutions in medtech, specifically in the areas of trauma, spine and joint reconstruction.
   
• Integra LifeSciences: The company pioneers in the field of regenerative medicine and offers advanced dermal matrices for wound care and reconstruction. The company is also known for its custom-made products for tissue regeneration used across complicated surgeries.
   

Biological Skin Substitutes Industry News:

• In March 2023, Arora Biosurgery announced to sign a group purchase agreement with Premier, for its Myriad and Symphony products. The agreement provides about 4400 U.S. hospitals and healthcare systems an easy access to the patented products that offer complex wound healing and soft tissue reconstruction.
   
• In April 2021, Aroa Biosurgery launched Myriad Morcells, a new product designed for tissue regeneration in wound beds. This launch helped the company to increase its product offerings and enhance its market presence.
   

The biological skin substitutes market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

By Type

• Human donor tissue-derived products
• Acellular animal-derived products
• Tissue-engineered skin products
• Biosynthetic skin products

By Application

• Acute wounds
• Chronic wounds
• Other applications

By End Use

• Hospitals
• Ambulatory surgical centers
• Specialty clinics
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • France
  • UK
  • Italy
  • Spain
• Asia Pacific 
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America 
  • Brazil
  • Argentina
  • Mexico
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE